Chemoinformaics analysis of (-)-Dihydrojasmonic acid
| Molecular Weight | 212.289 | nRot | 6 |
| Heavy Atom Molecular Weight | 192.129 | nRig | 7 |
| Exact Molecular Weight | 212.141 | nRing | 1 |
| Solubility: LogS | -2.347 | nHRing | 0 |
| Solubility: LogP | 2.328 | No. of Aliphatic Rings | 1 |
| Acid Count | 1 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 35 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 15 | No. of Aromatic Carbocycles | 0 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 1 |
| No. of Hydrogen atom | 20 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 12 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 35.7819 |
| nHD | 1 | BPOL | 21.8001 |
| QED | 0.688 |
| Synth | 3.083 |
| Natural Product Likeliness | 1.7 |
| NR-PPAR-gamma | 0.592 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.049 |
| Pgp-sub | 0.001 |
| HIA | 0.017 |
| CACO-2 | -4.73 |
| MDCK | 0.0000185 |
| BBB | 0.102 |
| PPB | 0.898372 |
| VDSS | 0.296 |
| FU | 0.0805338 |
| CYP1A2-inh | 0.03 |
| CYP1A2-sub | 0.749 |
| CYP2c19-inh | 0.016 |
| CYP2c19-sub | 0.541 |
| CYP2c9-inh | 0.023 |
| CYP2c9-sub | 0.967 |
| CYP2d6-inh | 0.004 |
| CYP2d6-sub | 0.353 |
| CYP3a4-inh | 0.008 |
| CYP3a4-sub | 0.08 |
| CL | 10.25 |
| T12 | 0.849 |
| hERG | 0.006 |
| Ames | 0.02 |
| ROA | 0.063 |
| SkinSen | 0.076 |
| Carcinogencity | 0.283 |
| EI | 0.814 |
| Respiratory | 0.064 |
| NR-Aromatase | 0.007 |
| Antiviral | Yes |
| Prediction | 0.60222 |